Tissue factor and tissue factor pathway inhibitor: A potential role in pregnancy and obstetric vascular complications?

Clinica Chimica Acta

Volumn 372, Issue 1-2, 2006, Pages 43-46

  Dusse, Luci Maria Sant'Ana ^a,d   das Graças Carvalho, Maria ^a   Cooper, Alan J ^b   Lwaleed, Bashir A ^c,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Gestational vascular complications; Pregnancy; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

PLACENTA PROTEIN 5; PROCOAGULANT; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLEEDING; BLOOD CLOTTING; CELL SURFACE; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; FIRST TRIMESTER PREGNANCY; HEMOSTASIS; HOMOZYGOSITY; HUMAN; MICROCIRCULATION; MONOCYTE; NONHUMAN; PLACENTA FUNCTION; PLACENTA VILLUS; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYNCYTIOTROPHOBLAST; THROMBOGENESIS; VASCULAR DISEASE;

ANIMALS; CELLS, CULTURED; FEMALE; HUMANS; LIPOPROTEINS; MICE; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOPLASTIN; VASCULAR DISEASES;

EID: 33747829629     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.03.025     Document Type: Review

References (40)

1. Butenas S., Bouchart B.A., Brummel-Ziedins K.E., Parhami-Seren B., and Mann K.G. Tissue factor activity in whole blood. Blood 105 (2005) 2764-2770
2. Spicer E.K., Horton R., Bloem, et al. Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci U S A 84 (1987) 5148-5152
3. Bangham A.D. A correlation between surface charge and coagulant action of phospholipids. Nature 192 (1961) 1197-1198
4. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 29 3 (1992) 170-176
5. Wilcox J.N., Smith K.M., Schwartz S.M., and Gordon D. Localization of tissue factor in the normal blood vessel wall and in atherosclerotic plaque. Proc Natl Acad Sci U S A 86 (1989) 2839-2843
6. Bach R.R., and Moldow C.F. Mechanism of tissue factor activation on HL-60 cells. Blood 89 (1997) 3270-3276
7. Poller L., and Thompson J.M. Clotting factors during oral contraception. Br Med J 2 (1966) 23-25
8. Satta N., Toti F., Feugeas O., et al. Monocytes vesiculation. A mechanism for dissemination of membrane-associated procoagulant activity and adhesion molecules after stimulation by LPS. J Immunol 153 (1994) 3245-3255
9. Bombeli T., Mueller M., and Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 77 (1997) 408-423
10. Hoppensteadt D.A., Walenga J.M., Fasanella A., Jeske W., and Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 77 (1995) 175-183
11. Broze G.J. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 6 (1995) 7-13
12. Broze G.J., Warren L.A., Novotny W.F., Higuchi D.A., Girard J.J., and Miletich J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa: Insight into its possible mechanism of action. Blood 71 (1988) 335-343
13. Girard T.J., Warren L.A., Novonty W.F., et al. Functional significance of the Kuntiz-type inhibitor domains of the lipoprotein associated coagulation inhibitor. Nature 338 (1989) 518-520
14. Lwaleed B.A., and Bass P.S. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 208 (2006) 327-339
15. Udagawa K., Yasumitsu H., Esaki M., et al. Subcellular localization of PP5 TFPI-2 in human placenta: a possible role of PP5 TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta 23 (2002) 145-153
16. Lanir N., Aharon A., and Brenner B. Haemostatic mechanisms in human placenta. Best Prac Res Clin Haematol 16 2 (2003) 183-195
17. Aharon A., Brenner B., Katz T., Miyagi Y., and Lanir N. Tissue factor and tissue factor inhibitor levels in trophoblast cells-implications for placental hemostasis. Thromb Haemost 92 (2004) 776-786
18. Erlich J.H., Parry G.C.N., Fearns C., et al. Tissue factor is required for uterine haemostasis and maintenance of the placental labyrinth during gestation. Proc Natl Acad Sci U S A (1999) 968138-968143
19. Chen J., Bierhaus A., Schiekofer S., et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 86 (2001) 334-345
20. Parry G.C., and Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not cytoplasmic domain. J Clin Invest 105 (2000) 1547-1554
21. Beller F.K., and Ebert C. The coagulation and fibrinolytic enzyme systems in normal pregnancy and the puerperium. Eur J Obst Gynecol Reprod Biol 13 (1982) 177-197
22. Lockwood C.J., Krikun G., Runic R., Schwartz L.B., Mesia A.F., and Schatz F. Progestin epidermal growth factor regulation of tissue factor expression during decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 85 (2000) 297-301
23. Uszynski M., Zekanowska E., Uszynski W., and Kuczynski J. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic and blood plasma: Implications for the mechanism of amniotic fluid embolism. Eur J Obstet Gynecol 95 (2001) 163-166
24. Thyzel E., Siegling S., Tinneberg H.-R., Gotting C., and Kleesiek K. Age dependent assessment of TFPI levels in follicular fluid of women undergoing IVF. Clin Chim Acta 361 (2005) 176-181
25. Hansen J.B., Olsen R., and Webster P. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood 90 (1997) 3568-3578
26. Holmes V.A., Wallace J.M., Gilmore W.S., MsFaul P., and Alexander H.D. Tissue factor expression on monocyte subpopulations during normal pregnancy. Thromb Haemost 87 6 (2002) 953-958
27. Holmes V.A., and Wallace J.M. Haemostasis in normal pregnancy: a balancing act?. Biochem Soc Trans 33 2 (2005) 428-432
28. Carmeliet P., Mackman N., Moons L., et al. Role of tissue factor in embryonic blood vessel development. Nature 383 (1996) 73-75
29. Bugge T.H., Xiao Q., Kombrinck K.W., et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 93 (1996) 62258-62263
30. Toomey J.R., Kratzer K.E., Lasky N.M., Stanton J.J., and Broze Jr. G.J. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 88 (1996) 1583-1587
31. Pederson B., Holscher T., Sato Y., Pawlinski R., and Mackman N. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 105 (2005) 2777-2782
32. Huang Z.F., Higuchi D., Lasky N., and Broze Jr. G.J. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90 (1997) 944-951
33. Chan J.C.Y., Carmeliet P., Moons L., et al. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. J Clin Invest 103 (1999) 475-482
34. Kanfer A., Bruch J.F., Nguyen G., et al. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and pre-eclampsia. Lab Invest 74 (1996) 253-258
35. Estelles A., Gilabert J., Grancha S., et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe pre-eclampsia. Thromb Haemost 79 (1998) 500-508
36. Bellart J., Gilabert R., Angles A., et al. Tissue factor levels and high ratio of fibrinopeptide A: D-Dimer as a measure of endothelial procoagulant disorder in pre-eclampsia. Br J Obstet Gynaecol 106 (1999) 594-597
37. Chen G., Wilson R., Wang S.H., Zheng H.Z., Walker J.J., and McKillop J.H. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 104 (1996) 154-159
38. Aharon A., Lanir N., Drugani A., and Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaprin treatment. J Thromb Haemost 3 (2005) 2355-2357
39. Schjetlein R., Abdelnoor M., Haugen G., Husby H., Sandset P.M., and Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 78 (1999) 191-197
40. Kuczynski J., Uszynski W., Zekanowska E., Soszka T., and Uszynski M. Tissue factor (TF) and tissue factor inhibitor activator (TFPI) in the placenta and myometrium. Eur J Obstet Gynecol Reprod Biol 105 (2002) 15-19